CannabCo believes its PureCann™ technology has the potential to create a new odorless cannabis segment within the cannabis industry. 

As the legalization of cannabis continues to open up new markets, the global cannabis marketplace is projected to grow to reach US$73.6 billion by 2027, according to Grand View Research. The medical segment of the cannabis market grew the most in 2019, growing by 71 percent as cannabis was embraced as a legitimate medical product for treating conditions including cancer, arthritis, Parkinson’s disease, Alzheimer’s disease, chronic pain and inflammation.


The emergence of cannabis as both a recreational product and a critical component of a number of medicines has contributed to the increase in research and development conducted in the cannabis space. While cannabidiol and the emergence of CBD-based treatments have dominated the medical cannabis segment, the recreational cannabis space has begun to experience its own influx of improvements as legal cannabis begins to benefit from a legal and regulated marketplace.

PureCann™ and Odorless Cannabis

Canadian cannabis innovator Cannabco Pharmaceutical is commercializing a cannabis production technology, called PureCann™, that is designed to create a pure form of cannabis by eliminating the harshness and extracting the unnecessary components of the plant. The company’s goal is to create an odorless cannabis product that can be carried and consumed discretely. “There is no question that there exists a huge demand for odorless products beyond the standard combustion of dry bud,” said Mark Novak, COO of CannabCo. “We are currently exploring numerous products both consumable, and non-consumable which will be produced from the manufacturing facility using PureCann™ as the base technology.” PureCann™ is exclusive to Cannabco.

The following infographic, sponsored by CannabCo Pharmaceutical, is designed to educate investors regarding innovations in the cannabis cultivation industry including the company’s PureCann™ technology.

Odorless CannabisOdorless CannabisOdorless CannabisOdorless CannabisOdorless Cannabis

Click here to connect with CannabCo Pharmaceutical Corp and to request an investor presentation.

This infographic is sponsored by Cannabco Pharmaceutical. This infographic provides information which was sourced by the Investing News Network (INN) and approved by Cannabco Pharmaceutical, in order to help investors learn more about the company. Cannabco Pharmaceutical is a client of INN. The company’s campaign fees pay for INN to create and update this infographic.

This infographic was created according to INN editorial standards to educate investors.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Cannabco Pharmaceutical and seek advice from a qualified investment advisor.

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less